Viriom China team participated in the 3rd China BioMed Innovation and Investment Conference in Suzhou

September 19th/ Suzhou/ Viriom China team participated in the 3rd China BioMed Innovation and Investment Conference in Suzhou. Ivan Solovyev presented Viriom’s plan on launching best in class HIV drugs in China – Elpida® –­ an effective, safe and well tolerated NNRTI with superior antiviral efficacy, resistance profile, pharmacokinetic properties, and VM1500A – a Long Acting Injectable Pre-Exposure Prophylaxis (PrEP). The breakthrough medicine, Elpida (Elsulfavirine) was already approved in a number of countries worldwide for treatment of HIV1 infection. These product developments and new CFDA regulations may create a potential for  Viriom to fast track towards obtaining a market authorization  of   Elpida® in China.

China BioMed Innovation and Investment Conference is one of the most reputable BioMed industry events. This year CBIIC gathered more than 5000 participants and representatives of more than 700 pharmaceutical companies.

Viriom Inc. met and discussed its programs at the conference with Chinese development, marketing and investment partners.

About Viriom

Viriom Inc. is a commercial and late-stage development biotech company researching, manufacturing and distributing novel and affordable therapies and prophylaxis against life-threatening infections such as HIV and HBV. Viriom holds a an exclusive worldwide license  from F. Hoffmann-La Roche for elsulfavirine to treat HIV1 infection, and long acting injectable    VM1500A drug candidate for treatment and prevention of HIV infection in high-risk patient populations. Viriom is also developing proprietary dual and triple fixed dose regimens; VM3500 a long acting integrase strand transfer inhibitor drug candidate for treatment of HIV1 infection and VM2500 a potentially best in class pro-drug tenofovir  for treatment of HIV and HBV infections. Viriom established its China subsidiary in Beijing in June 2018 and started to develop its products in Chinese FDA.

For more information, please visit


PR manager Xi Ailing